• Solid published its annual report on Form 10-K, reporting a net loss of USD 174.33 million.
• Research and development expense rose 45.5% to USD 140.33 million, driven primarily by higher SGT-003 manufacturing and clinical costs and higher personnel-related expenses.
• General and administrative expense increased 16.8% to USD 38.88 million, mainly reflecting higher personnel-related costs and information technology support and services.
• Cash, cash equivalents and available-for-sale securities totaled USD 187.9 million, and Solid said net proceeds of about USD 226.4 million from a March 2026 private placement are expected to fund operations into the first half of 2028.
• Pipeline updates included 41 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 with one treatment-related serious adverse event reported, and the company expects first dosing in its Phase 3 IMPACT DUCHENNE trial in April 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-115928), on March 19, 2026, and is solely responsible for the information contained therein.